Hepatocellular adenoma: When and how to treat? Update of current evidence by Thomeer, M.G.J. (Maarten) et al.
Therapeutic Advances in Gastroenterology
898 http://tag.sagepub.com
Ther Adv Gastroenterol
2016, Vol. 9(6) 898 –912
DOI: 10.1177/ 
1756283X16663882
© The Author(s), 2016. 
Reprints and permissions:  
http://www.sagepub.co.uk/
journalsPermissions.nav
Creative Commons Non Commercial CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/
licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the 
SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction
Hepatocellular adenomas (HCAs) are an uncom-
mon, solid, benign tumor of the liver, with an 
estimated incidence of 3–4 per 100,000 women 
[Bioulac-Sage et al. 2010]; this frequency is based 
on population research including women using 
oral contraceptives (OCs) [Baum et al. 1973]. A 
causal role for hormone activity in HCA growth is 
suggested by data linking adenoma regression to 
the cessation of OC use, and growth associated 
with pregnancy [Cobey and Salem, 2004].
Typically, HCAs are treated conservatively, with 
patients advised to avoid oral contraception. The 
risks of growth and rupture of HCAs during preg-
nancy has to be underlined, especially in larger 
HCAs. Tumor progression, suggested by internal 
bleeding and malignant transformation, necessi-
tates a more aggressive therapeutic approach, with 
lesions larger than 5 cm considered as the primary 
risk factor [Marrero et al. 2014]. The introduction 
of a new subclassification system for HCA has 
been suggested to help clinicians to stratify patients 
according to imaging criteria, expression of associ-
ated immunohistochemical markers or molecular 
findings. These data may influence the treatment 
selected [Marrero et al. 2014] since certain sub-
types of HCA pose a greater risk of progression to 
hepatocellular carcinoma (HCC) than others. For 
example, a subtype of HCA defined by the reduced 
expression of liver fatty acid-binding protein 
(LFABP) ordinarily indicates a subtype with a less 
aggressive course and a tendency towards a benign 
phenotype.
Based on the recent literature, we describe the 
impact of this newly instigated HCA subclassifi-
cation, and discuss whether this knowledge, com-
bined with imaging data, improves our risk 
analyses for patients with HCA. Furthermore, we 
outline the different therapeutic options indicated 
by each HCA subtype.
The Bordeaux classification of HCA
In recent years, four distinct subtypes of HCA 
have been recognized: inflammatory HCA (40–
50%, IHCA), HNF1A-mutated HCA (30–40%, 
H-HCA), β-catenin activated HCA (10–15% 
b-HCA), and unclassified HCA (10–25%, 
UHCA) [Nault et  al. 2013]. In these different 
subtypes, several genetic mutations are identified, 
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causing (benign) proliferation of hepatocytes and 
in some HCA, malignant transformation [Pilati 
et al. 2014].
Patients presenting with IHCA demonstrate both 
serum, and lesional indicators of an active inflam-
matory response. In these lesions, increased 
expression is seen of the markers serum amyloid A 
and C-reactive protein, both classic indicators of 
the acute phase response [Bioulac-Sage et  al. 
2007a]. Patients within this HCA category fre-
quently demonstrate increased body weight, and a 
high alcohol intake [Bioulac-Sage et  al. 2007b, 
2009; Paradis et al. 2007]. In approximately 10–
20% of these lesions, a β-catenin mutation is 
found [van Aalten et al. 2011b]. 
A second subtype of HCA, H-HCA, is character-
ized by a downregulation of the LFABP; this phe-
notype, which is not apparent in the other HCA 
subtypes, rarely leads to malignant progression 
[Zucman-Rossi et al. 2006].
Subtype b-HCA is typified by activating muta-
tions of β-catenin that resist phosphorylation-
mediated down-regulation by the GSKB/APC/
AXIN complex [Nault et  al. 2013]. Particularly 
the exon 3 mutation of β-catenin plays a signifi-
cant role in malignant progression in contrast to 
exon 7/8 mutations [Pilati et al. 2014]. The result 
is an accumulation of nuclear β-catenin which, 
combined with deletion of APC, favors progres-
sion to HCC [Nault et al. 2013]. The compara-
tively small number of β-catenin positive nuclei 
can lead to this phenotype being overlooked in 
small biopsies [van Aalten et  al. 2011b]. The 
b-HCA subtype also demonstrates an overexpres-
sion of glutamate-ammonia ligase (GLUL) 
encoding glutamine synthase (GS), which can be 
used as a sensitive diagnostic biomarker for this 
subtype [van Aalten et al. 2011b].
The final subtype, UHCA, is not yet defined by 
any specific genetic mutation, but is instead char-
acterized by various histologic criteria that are 
unusual in the other subtypes; the underlying 
pathogenesis of this subtype remains unclear 
[Blanc et al. 2015].
Magnetic resonance imaging of the different 
subtypes of HCA
The primary differential diagnosis for HCA is 
focal nodular hyperplasia (FNH). If in doubt, a 
biopsy should be taken, especially for larger 
lesions, as the clinical management will differ for 
either pathology. In most cases these diagnoses 
can be differentiated according to signal intensity 
and dynamic vascular patterns after intravenous 
aspecific gadolinium injection [(conventional 
magnetic resonance imaging (MRI)] [van Aalten 
et al. 2011a]. Different patterns can be used for 
confident diagnosis as proposed by Thomeer and 
colleagues [Thomeer et al. 2014a].
In more challenging cases, specific hepatobiliary 
contrast agents can be used. Currently there are 
two agents available, gadobenate dimeglumine, 
and gadoxetate disodium [Grazioli et  al. 2013; 
Thomeer et al. 2014a; McInnes et al. 2015]. If the 
lesion turns hypointense to the surrounding liver 
in the hepatobiliary phase, FNH can be excluded 
in most cases. If the lesion becomes iso- to hyper-
intense the differential diagnosis is FNH or in 
exceptional cases HCC. However, it should be 
noted that IHCA can also be isointense in the 
hepatobiliary phase [Agarwal et al. 2014; Thomeer 
et  al. 2014b]. This might be explained by the 
presence of internal bile duct proliferation, previ-
ously thought to be only visible in FNH. This 
diagnostic pitfall can be visualized when using 
gadobenate dimeglumine [Thomeer et al. 2014b], 
or gadoxetate disodium [Agarwal et al. 2014]. A 
recent systematic review about the value of gadox-
etate disodium has shown that apart from this pit-
fall, adequate differentiation is possible in most 
cases [McInnes et al. 2015]. It was reported that 
the hepatobiliary phase has a sensitivity of 91–
100% and a specificity of 87–100% for differenti-
ating HCA from FNH. In the largest study this 
was only seen in 13% of cases [Bieze et al. 2012].
In conclusion, in the vast majority lesions can eas-
ily be differentiated based on a combination of 
typical findings on conventional MRI and fea-
tures on hepatobiliary phase MRI.
Some typical MRI features allow us to discrimi-
nate different subtypes of HCA (Table 1): IHCA 
can be hyperintense on T2-weighted images, with 
persistent enhancement on delayed imaging in 
the venous phase [Laumonier et al. 2008]. Ronot 
and colleagues validated this feature as being 
highly specific for IHCA, with a sensitivity of 
82% [28/34, confidence interval (CI) 65–93%], 
and an optimal specificity of 100% (12/12, CI 
75–100%) [Ronot et al. 2011]. Another diagnos-
tic indicator for IHCA is the atoll-sign [van Aalten 
et al. 2011a], a hyperintense rim on T2-weighted 
images at the periphery of the lesion (resembling 
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an atoll) that is enhanced late in the venous phase. 
This feature is present in 27% of IHCAs in this 
study [van Aalten et al. 2011a].
Whilst H-HCAs are typically characterized by a 
large amount of aberrant fat which can be readily 
appreciated by out-of-phase imaging, or on a fat-
saturated T1-weighted image [Laumonier et  al. 
2008; van Aalten et al. 2011a], van Aalten and col-
leagues failed to detect fat by MRI for as many as 
22% of cases (2/9) [van Aalten et al. 2011a]. Ronot 
and colleagues validated the diagnostic feature of 
diffuse and homogeneous signal dropout on out-
of-phase T1 weighted imaging, with a reported 
sensitivity of 90% (10/11, CI 58–99), and specific-
ity of 88% (32/36, CI 73–96) [Ronot et al. 2011]. 
The main drawback of this marker is that diffuse 
intralesional steatosis may also be present in up to 
11% (4/34) of IHCAs [Ronot et  al. 2011], 
although, according to the authors, this does not 
represent a major pitfall as fat is usually distributed 
heterogeneously within IHCAs (Figure 1).
The MRI features of b-HCA are not well defined, 
principally because these lesions are compara-
tively rare. Van Aalten and colleagues reported 
poorly delimited, high-signal intensity areas, to be 
typical of this subtype (5/7, 71%), but additional 
investigations are warranted [van Aalten et  al. 
2011a]. Table 2 shows the various MRI features 
reported in the literature for b-HCA, although, 
where reported, these features are inconsistent. 
Despite significant numbers of false negatives, the 
specificity of these MRI features is very high, lead-
ing us to conclude that if any one of these signs are 
present, a diagnosis of the corresponding MRI 
subtype can be made with some certainty. Larger 
datasets will be needed to determine the true value 
of MRI in HCA imaging for all subtypes; cur-
rently, this technique is of most use in evaluating 
prognosis.
Reviewing the known complications
Intralesional bleeding
On reviewing the recent literature, van Aalten 
and colleagues detected evidence of hemorrhage 
in 27.2% of all patients (315/1160) with one or 
more HCAs, giving a 15.8% chance of hemor-
rhage for every HCA (118/748) [van Aalten et al. 
2012]. Acute rupture and intraperitoneal bleed-
ing were reported in 17.5% of patients. A size 
for the smallest HCAs showing hemorrhage was 
reported for 13 of the 28 articles reviewed; 
Table 1. Typical MRI findings according to subtypes 
of HCA.
Subtype Most typical MRI signs
IHCA Hyperintense on T2-weighted images, 
with persistent enhancement in the 
venous phase;
atoll sign
H-HCA Diffuse and homogenous fat deposition 
(Figure 1)
b-HCA (Vaguely demarcated scar)
UHCA No typical sign
b-HCA, β-catenin activated HCA; HCA, hepatocellular 
adenoma; H-HCA, HNF1A-mutated HCA; IHCA, inflam-
matory HCA; MRI, magnetic resonance imaging; UHCA, 
unclassified HCA.
Figure 1. In- and out-of-phase MRI of a typical case 
of histochemistry proved H-HCA which was resected. 
Note the diffuse and homogenous signal drop-off 
on the out-of-phase image (a) versus the in-phase 
image (b). This correlates with diffuse intralesional 
fat identified by histology. MRI differentiation between 
H-HCA and IHCA would not be possible when the 
signal drop is more heterogeneous.
HCA, hepatocellular adenoma; H-HCA, HNF1A-mutated 
HCA; IHCA, inflammatory HCA; MRI, magnetic resonance 
imaging.
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hemorrhage generally arose in the larger lesions 
(>5 cm), although smaller lesions could also 
bleed (Table 3), albeit at much lower rates. These 
data should be interpreted with caution, as only 
the resected cases were included. The actual 
chance of bleeding in the different subtypes is 
likely to be significantly lower. The risk of bleed-
ing was inconsistent across the subtypes of HCA: 
IHCA showed a higher propensity for macro-
scopic hemorrhage (30%), than H-HCA (8%) 
[Dokmak et al. 2009] which can presumably be 
attributed to the larger number of venous struc-
tures, or telangiectatic changes in this subtype.
Although there may be a difference in prevalence 
of internal bleeding, all subtypes bear this intrin-
sic risk [Laumonier et  al. 2008; Dokmak et  al. 
2009; Ronot et al. 2011; van Aalten et al. 2011b], 
which diminishes the utility of subtype classifica-
tion in terms of the clinical management of this 
risk. Furthermore, more data are needed to prove 
any correlate between reduced bleeding and the 
H-HCA subtype.
Bieze and colleagues described a series of 45 
patients with 195 lesions. In this cohort, there 
was a tendency to an enhanced risk of bleeding 
when the lesion was located in the left lateral liver 
(11/32 versus 31/163 in other regions), and 
showed exophytic growth (16/24 versus 9/82) 
[Bieze et al. 2014] (Figure 1). The latter phenom-
enon is probably due to the subcapsular location, 
with no intrinsic capsule, and minimal surround-
ing liver with which to prevent rupture of the 
Table 2. Recently published b-HCAs with their typical characteristics defined by MRI. Note the low prevalence 
in the literature of MRI data, with inconsistent findings.





2012 7 Vaguely defined scar on T2W sequences (3 cases)
[Laumonier 
et al. 2008]
2008 5 Marked hyperintensity on T2W sequences and 
persistent delayed enhancement (3 cases)
Isointensity on T2W sequences, with strong arterial 
enhancement and delayed washout (2 cases)
[Yoneda et al. 
2012]
2012 1 Vaguely defined scar on T2W sequences
b-HCA, β-catenin positive HCA; HCA, hepatocellular adenoma; MRI, magnetic resonance imaging; T2W, T2-weighted.
Table 3. Summary of the findings of an earlier review of 12 articles in which the percentage of hemorrhaged 
HCAs, and minimal lesion sizes, were reported. Hemorrhage occurred mostly in larger HCAs (>5 cm; 
minimally 42.2%), but smaller lesions also showed some bleeding (range 8.3–11.5%).
Series Patients with 
hemorrhaged HCA
Size of smallest 
HCA (cm)
Percentage <5 cm 
of total (%)
[Reddy et al. 2001] 3 of 25 4 –
[Hung et al. 2001] 4 of 25 4.2 –
[Toso et al. 2005] 10 of 25 1.7 –
[Cho et al. 2008] 12 of 41 1 8.3 (1/12)
[Bioulac-Sage et al. 2009] 23 of 128 <5 –
[Edmondson et al. 1976; Dokmak et al. 2009] 26 of 122 <5 11.5 (3/26)
[Edmondson et al. 1976] 10 of 42 >5 0
[Leese et al. 1988] 2 of 24 5 0
[Ault et al. 1996] 4 of 12 6 0
[Closset et al. 2000] 7 of 16 7 0
[Deneve et al. 2009] 31 of 124 >5 0
[Chung et al. 1995] – 5 0
HCA, hepatocellular adenoma.
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hematoma into the abdominal cavity. However, 
no other data are available to support this theory, 
and preventive treatment in these cases does not 
appear to be warranted.
As for the clinical application of these findings, 
there is no evidence that supports the use of sub-
type classification in the stratification and man-
agement of individual patients. Moreover, size 
still remains the most important marker to predict 
those at risk for larger bleeding in follow up.
Malignant transformation
Malignant transformation of HCA to HCC is 
rarely reported, but is an accepted risk, particularly 
when the diameter of the adenoma exceeds 5 cm 
(Figure 2) [Stoot et al. 2010; Grazioli et al. 2013]. 
In a systematic review, Stoot and colleagues 
reported an overall frequency of malignant trans-
formation of 4.2% for HCAs [Stoot et  al. 2010] 
(67 of 1635 HCAs, CI 0–100%). Only three cases 
showed malignant transformation for tumors <5 
cm in diameter, which represented 4.4% of the 
total number of HCCs arising from HCAs (3 out 
of 67). As suggested for the internal bleeding data, 
these reports should be interpreted with caution.
Of the four HCA subtypes, (exon 3) b-HCAs are 
known to trigger a potent mitogenic signaling 
pathway that is prominent in HCC [Zucman-
Rossi et  al. 2007; Chu and Moon, 2013; Pilati 
et al. 2014], which suggests a positive correlate 
between the two. Zucman-Rossi and colleagues 
reported an incidence of HCCs, or borderline 
malignant tumors in b-HCAs, of up to 46%; this 
malignant progression was seldom seen in other 
subtypes [Zucman-Rossi et  al. 2007], and was 
over-represented for male patents (5 cases, 38%; 
p = 0.02) [Hussain et  al. 2006]. Since the 
β-catenin pathway can also be activated in IHCA 
[van Aalten et al. 2011b], both the b-HCA and 
IHCA subtypes may necessitate more aggressive 
treatment than either the H-HCA or UHCA, 
although the clinical relevance of this determina-
tion has yet to be broadly accepted. In follow up, 
malignant progression of HCA to HCC has only 
rarely been demonstrated, with questionable 
quality of the imaging data for those rare, 
reported cases. Therefore it is presently difficult 
to prove that HCC is a transition from HCA, 
although the presence of β-catenin has been sug-
gested as a criterion for the selection of HCA, or 
well-defined HCC, for resection [Bioulac-Sage 
et al. 2013]. Interestingly, Figure 2 shows a lesion 
with a typical nodule-in-nodule appearance 
which suggests a form of transition from HCA to 
HCC. Another problem is that corroboration of 
the pathology is seldom available, due to the fact 
that biopsies of HCA are rarely performed, with 
diagnoses generally made with MRI [Hussain 
et  al. 2006]. A final diagnosis of b-HCA based 
solely on MRI findings would be helpful, but the 
MRI findings published to date for this subtype 
are sparse (Table 2). Finally, it should be men-
tioned that HCA shows a higher risk of malig-
nant transformation in men [Farges et al. 2011]. 
In these cases, the possibility of hepatitis, an 
underlying glycogen storage disease (Figure 3), 
or sex steroid hormone abuse, should all be con-
sidered as all predispose to HCC [Yoneda et al. 
2012]. A more aggressive treatment is advised in 
such cases, even for lesions <5 cm.
Finally, according to the recent literature, H-HCA 
almost never degenerate into HCC, although 
some very rare cases have been reported [Stueck 
et al. 2015]. The low risk of H-HCA degeneration 
may help to simplify the management of liver ade-
nomas as will be discussed later.
As for clinical application, mainly b-HCA and 
IHCA are prone to malignant degeneration, and 
mostly if >5 cm. In these instances, invasive 
treatment is recommended.
Pregnancy
Women with HCA who are pregnant, or wish to 
become pregnant (Figure 4), should be closely 
monitored for HCA size (with ultrasound or 
MRI) during their pregnancy, due to the ten-
dency of the lesion to grow, especially during the 
third trimester when high levels of estrogens are 
present [Cobey and Salem, 2004]. Hormone-
induced growth, and possible rupture, may result 
in potentially lethal complications for the mother 
and unborn child. Treatment of HCA during 
pregnancy may be indicated when the lesion 
shows signs of growth or bleeding, however spe-
cific figures for the risk of HCA complication dur-
ing pregnancy are not yet available.
Whether some subtypes are more prone to com-
plications during pregnancy is not known, 
mainly because the majority is diagnosed 
non-invasively.
The choice of follow up, surgery, radiofre-
quency ablation (RFA) or transcatheter arterial 
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embolization (TAE) for the treatment of HCAs 
in pregnancy is often a matter of debate. Surgery 
of lesions located at the periphery of the liver 
can be performed safely within the first or sec-
ond trimester, and will usually be indicated by 
the size of the lesion, and its change in size. 
Radiation exposure or exposure to iodinated 
contrast media during RFA or TAE may be 
contraindicated during the early phase of preg-
nancy, with the treatment of smaller lesions not 
being indicated. Given the increased risk of 
hemorrhage in larger HCAs (>5 cm), or when 
a previous pregnancy was complicated by either 
minor or major bleeding, we currently advocate 
a preemptive treatment strategy before preg-
nancy, as proposed by Broker and colleagues 
[Broker et al. 2012]. Whenever a HCA is dis-
covered during pregnancy, the second trimester 
is the optimal moment for invasive treatment, if 
indicated, as anesthesia is well tolerated at this 
Figure 2. A 32-year-old female using oral contraceptives with a 11 cm lesion in the liver. Based on MRI this 
lesion was compatible with a HCA. However, both on T2-weighting (Figure 1(a)) as on the images after contrast 
injection the lesion appeared heterogeneous with a focus of diffusion restriction (typically a low ADC value, (b)). 
Diffusion restriction is thought to be a typical sign of malignancy in liver lesions. Based on the findings above 
and because the lesion was larger than 5 cm, the lesion was resected 3 months later. On gross pathology 
there was a focal nidus (Figure 1(c), arrow, concordant with the nidus on MRI) which appeared to be an HCC 
in a HCA (‘nodule-into-nodule’). On histology (H–E × 25, (d)) at the interface HCA/HCC, the upper part of the 
tumor showed proliferation of hepatocytes without obvious cytological anomalies, intermingled with thin/
isolated vessels (down side of dotted line), favoring an HCA. ‘Nodule-into-nodule’ consists of clearer cells 
with mild atypia (above dotted-line, (d)), disorganized or decreased reticulin fibers (e) and obvious positivity 
for Glypican-3 (f), favoring an HCC (well differentiated). (g) GS-staining pattern at the periphery of the HCA. 
Glypican-3, Serum Amyloid A and CRP were negative in the HCA. β-catenin staining showed only membranous 
expression. Based on the above we interpreted this HCA as a b-HCA.
CRP, C-reactive protein; HCA, hepatocellular adenoma; HCC, hepatocellular carcinoma; GS staining, glutamine synthetase 
immunostaining indicative of b-HCA; MRI, magnetic resonance imaging.
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stage, and the fetus is not yet so large as to 
interfere with liver surgery [Parangi et al. 2007].
Liver adenomatosis
Hepatic adenomatosis (HCAs more than 10) is 
regarded by some authors as a different entity 
[Barthelmes and Tait, 2005; Frulio et al. 2014]. 
There seems not to be a strong association with 
estrogen or anabolic steroid use [Chiche et  al. 
2000; Grazioli et al. 2000]. However, there is a 
strong association with glycogen storage disease 
[Chiche et al. 2000; Frulio et al. 2014]. Mostly, 
these adenomas are of the H-HCA and IHCA 
subtypes [Frulio et  al. 2014]. The nodules in 
hepatocellular adenomatosis are often of the same 
Figure 3. A 50-year-old male with multiple hypervascular lesions. These lesions were diagnosed as HCA 
or HCC based on imaging and clinical (glycogen storage disease) findings. (a) An axial MR image, with T1 
weighting, after contrast injection in the arterial phase. In segment 5, a small lesion with a cystic central 
portion (large arrow) was biopsied, and subsequently diagnosed as HCC following positive GS staining with 
negative β-catenin staining. Posteriorly, a second, smaller lesion was visualized (<1 cm, small arrow). 
Histologic sample of a lesion with diffuse GS-positivity (b). Axial MR image with T1-weighing after contrast 
injection in the arterial phase (c). In this image, taken 3 years later, the second lesion has grown (now 
3 cm, small arrow). The large arrow shows the resection/ablated part of the liver (from lesion 1). A new 
hypervascular lesion (curved arrow) was also detected outside the liver, which proved to be a trajectory 
metastasis. These lesions (large arrow, curved arrow) were successfully ablated. This patient is currently 
being followed at regular, short intervals, and is on the waiting list for a liver transplantation.
GS staining, glutamine synthetase immunostaining indicative of b-HCA, even with a negative β-catenin staining; HCA, 
hepatocellular adenoma; HCC, hepatocellular carcinoma; MR, magnetic resonance.
Figure 4. A 25-year-old female with a MRI diagnosis of single HCA, probably inflammatory subtype. As 
the patient wished to become pregnant, despite growth of her HCA, a decision to treat with TAE was taken. 
Coronal MR image with T1-weighting of the upper abdomen (a). A hypervascular HCA is indicated (small 
arrow), adjacent to the gallbladder (long arrow). Ablation was contraindicated due to the close proximity of 
the gallbladder. Angiogram (b) before TAE showing an arterial tumor ‘blush’ in the HCA (short arrow), with the 
gallbladder perfused by the same local hepatic artery division (long arrow). This finding contraindicated TAE 
due to the possibility of gallbladder necrosis following infarction. Instead, a decision to operate was made, with 
resection of the gallbladder, and subsequent intraoperative RFA of the HCA. Axial postoperative CT image after 
contrast injection in the venous phase (c). The gallbladder was resected, in combination with intraoperative 
RFA (arrow).
CT, computerized tomography; HCA, hepatocellular adenoma; RFA, radiofrequency ablation; TAE, transcatheter arterial 
embolization.
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subtypes. Although one might assume that multi-
ple HCAs increase the propensity for lesional 
bleeding, previous data have shown no significant 
difference in macroscopic bleeding between sin-
gle and multiple HCAs (p < 0.155) [Dokmak 
et al. 2009]. According to literature there seems 
to be no indication to suggest that the risk of 
malignant transformation is increased in hepatic 
adenomatosis compared with solitary HCAs 
[Barthelmes and Tait, 2005]. However, hepatic 
adenomatosis are more often found in glycogen 
storage disease and in man [Chiche et al. 2000], 
and as such at risk for increased malignant poten-
tial. Presently, there is no systematic review avail-
able which evaluates the malignant potential of 
hepatic adenomatosis. As for clinical manage-
ment, and there are no data suggesting that 
hepatic adenomatosis should be treated differ-
ently from solitary HCAs.
Biopsy in the management of HCA
Since the introduction of the HCA subclassifica-
tion system, several authors have attempted to 
further refine the diagnostic work-up using addi-
tional techniques, including immunohistochemis-
try [Zucman-Rossi et  al. 2006]. The primary 
motivation for the introduction of additional 
biopsies was the prospect of identifying HCAs 
with greater malignant potential (such as exon-3 
β-catenin mutated HCAs). There seem to be no 
unique MRI features with which to assign a 
b-HCA subtype risk, which offers one argument 
for the expansion of the use of diagnostic biopsy 
in order to arrive at a correct diagnosis.
However, at present there is no consensus 
regarding the diagnostic work-up of HCA [Nault 
et al. 2013; Marrero et al. 2014]. Nault and col-
leagues regard histologic analysis as the back-
bone of HCA diagnosis, with the detection or 
exclusion of b-HCA as the main input [Nault 
et  al. 2013]. They argue that biopsy should be 
offered in all cases of HCA <5 cm with no typi-
cal MRI sign of H-HCA. Lesions >5 cm do not 
require biopsy since they are all preferably 
resected. In our opinion, and in accordance with 
recent American College of Gastroenterology 
guidelines for liver lesions, the diagnostic workup 
of suspected HCA should be based primarily on 
MRI findings, with biopsy in cases where the 
lesion cannot be clearly differentiated from FNH 
[Marrero et  al. 2014]. Other indications for 
biopsy are an atypical presentation of the HCA 
on imaging, with the main differential diagnosis 
being HCC in a noncirrhotic liver [Marrero et al. 
2014].
The biopsy of all HCAs (with the exclusion of 
typical H-HCAs based on MRI) found by imag-
ing would be impractical. Most patients with 
HCA are young, with minor symptoms on malig-
nant progression; invasive procedures should 
preferably be avoided. While the risk of bleeding 
complications is very low when using an 18G core 
needle biopsy (0.6%) [Haage et al. 1999; Kadri 
Aribas et al. 2010; Aribas et al., 2012], the risks 
are not negligible, and deaths due to bleeding 
complications have been reported [Stattaus et al. 
2007]. In our practice a biopsy has not been per-
formed to date, except where the diagnosis of a 
specific adenoma subtype was expected to alter 
clinical management.
Unquestionably, a biopsy for further characteri-
zation may add important information in well-
defined cases. For example, a biopsy with the 
additional help of immunostaining could facili-
tate better discrimination between HCA and 
FNH, as shown in a large retrospective study in 
France where the investigators compared biopsies 
against a final diagnosis based on surgical resec-
tion [Bioulac-Sage et  al. 2012]. A total of 239 
needle biopsies were compared with the final 
diagnosis made on resection. A difference in sen-
sitivity of 74.3% with immunostaining versus 
58.6% achieved with routine analyses without GS 
or other molecular features was reported [Bioulac-
Sage et al. 2012]. These data suggest that immu-
nostaining should be made available in centers 
that routinely treat HCAs.
What is the best approach in cases where differen-
tiation between HCA and HCC is not evident 
based on MRI? In cases where there is a major 
suspicion of malignancy (e.g. HCC in noncir-
rhotic liver) based on a combination of clinical 
findings, size of the lesion, increased serum 
α-fetoprotein, and MRI findings (such as hetero-
geneous presentation with heterogeneous 
enhancement, washout, and true capsule) (Figure 
2), resection without prior biopsy can be recom-
mended. Although biopsy of each suspect lesion 
would undoubtedly help in detecting HCC, this 
approach may be impractical due to the significant 
level of false-negative findings, the chances of 
seeding (Figure 3), and the enhanced risk of 
bleeding, which is particularly relevant when mul-
tiple biopsies are taken. Furthermore, in cases 
with a typical presentation, a biopsy will not 
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influence the decision to remove the lesion. 
Therefore, we suggest to biopsy in selected cases 
only. Interestingly, the HCC literature documents 
a similar debate on whether it is acceptable to 
diagnose HCC in a cirrhotic liver based solely on 
MRI findings, or whether the use of routine biop-
sies should be advocated for all suspected lesions 
in patients with liver cirrhosis [Sherman and 
Bruix, 2015; Torbenson and Schirmacher, 2015]. 
Even in high grade dysplastic nodes, follow up by 
imaging is still preferred above biopsies.
As for daily practice, we recommend biopsy only 
in very selected cases where HCA cannot be dif-
ferentiated from FNH with any imaging modal-
ity. The clinical repercussion of a wrong diagnosis 
of either HCA or FNH can have a large influence 
on a patient’s future in terms of treatment and 
prognosis. When there are signs of malignancy 
patients should preferentially be forwarded to an 
experienced referral center for further evaluation. 
One should be aware that in some cases MRI or 
biopsy will be unable to differentiate between 
HCA and well-differentiated HCA.
Treatment options for HCA
Historically, HCAs were treated with a wait-and-
see policy, with surgical intervention preferred for 
larger (>5 cm) growing tumors. Current manage-
ment options for HCAs may also include RFA, 
and TAE, mainly due to the advantages of these 
minimally-invasive techniques. In the following 
section we will discuss routine, as well as less 
commonly used HCA treatment options, with a 
focus on minimally-invasive, image-guided, treat-
ment options.
Conservative treatment
When HCAs are <5 cm, or regress (to <5 cm) 
following cessation of OCs, with no further 
growth detected, a wait-and-see policy is war-
ranted. Although no widely accepted approach 
has yet been published, we prefer to schedule a 
patient for follow up, including MRI, or ultra-
sound in a yearly follow up until menopause.
Surgery
Surgery has long been considered the treatment 
of choice because complete surgical removal of 
the lesion can be achieved in a controlled and 
relatively safe manner. Elective surgical resection 
is considered for all lesions >5 cm in diameter. 
With a mortality of 1.1% (review by Lin and col-
leagues, n = 170), surgery is a relatively safe pro-
cedure. In one review, 93% of patients with 
ruptured, or nonruptured HCAs, were primarily 
treated with surgery, with complications that 
included two deaths, one biloma, one bile leak-
age, one infection, and one case of sepsis [Lin 
et al. 2011]. In another, single-center retrospec-
tive analysis of 41 cases, no perioperative mortal-
ity was found, and only minor complications 
arose. These included pleural effusion requiring 
drainage (n = 2), pneumonia (n = 1), and wound 
infection (n = 1) [Cho et al. 2008].
In the latter study, nine cases were operated on 
laparoscopically, a technique that is increasingly 
popular, where appropriate. De’Angelis and col-
leagues described 62 HCA patients who under-
went either an open procedure or laparoscopy 
[De’Angelis et  al. 2014]. They found no differ-
ence in postoperative morbidity and zero mortal-
ity, with no longterm complications or recurrence 
of HCA. However, patients with smaller lesions 
were preferentially treated with laparoscopy (68 
versus 9). These authors concluded that laparo-
scopic liver resections may be limited by lesion 
size and location, and that the technique requires 
advanced surgical skills. Given the precision 
required, robotic surgery may prove to be useful 
in the future, and could reduce complications; we 
await further evaluation of its efficacy [Jackson 
et al. 2015].
In rare circumstances, the treatment of HCA may 
also involve liver transplantation, a procedure 
described in a case report by Venarecci and col-
leagues [Vennarecci et al. 2013]. Obesity, steatosis, 
and diabetes, are frequent co-morbidities in 
patients with HCAs, particularly the inflammatory 
subtype. These factors, and especially obesity, 
make surgery less attractive. For those patients 
who are poor candidates for surgery (centrally-
located lesions, multiple adenomas, or morbid 
obesity), RFA and TAE may instead be offered.
Radiofrequency ablation
RFA is a minimally invasive technique used in the 
treatment of HCC, other liver lesions such as 
colorectal metastases [Solbiati et al. 2001; Cabibbo 
et al. 2013], and HCAs [van Aalten et al. 2010; 
van Vledder et  al. 2011]. Laparoscopic RFA, or 
perioperative RFA, may also be considered when 
the anatomical location [i.e. close proximity to the 
bowel or gallbladder (Figure 3)] leads to an 
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increased risk using a percutaneous approach. 
The use of RFA in the treatment of HCAs has 
only been described in small case series.
Van Vledder and colleagues described one case 
series including 45 HCAs, in 18 patients, that 
were ablated in 32 RFA sessions (open, n = 4; 
percutaneous, n = 28) [Van Vledder et al. 2011]. 
A total of 26 of 45 HCAs were successfully treated 
in one RFA session, with no visible residual dis-
ease. A further nine HCAs were totally ablated 
following a second RFA session. There were 3 
HCAs that required 3 or more RFA sessions, with 
all but 7 of the 45 HCAs totally ablated after 3 or 
more sessions. The treated HCAs had a median 
size of 3.0 cm (ranging from 0.8 to 7.3 cm). Only 
minor complications were attributable to the RFA 
procedure; none of which required additional 
intervention (class A according to the Society of 
Interventional Radiology scoring system for com-
plications). A single class D major complication 
was reported; a cerebrovascular accident during 
open surgery combined with RFA. Though severe, 
this complication was linked to anesthesiological 
and hemodynamic changes during laparotomy, 
rather than the RFA procedure. In conclusion, 
RFA can be effectively and safely used in the treat-
ment of HCA, although multiple sessions may be 
required for larger lesions.
In a review of HCA cases reported between 1998–
2008, Lin and colleagues identified 356 HCA 
patients in reports from China, Europe, North 
America, and South-East Asia [Lin et al. 2011]. 
Only 14 (3.9%) of these cases were treated with 
RFA, and no severe complications were reported. 
However, no results in terms of efficacy were pro-
vided. In 2008, Rhim and colleagues. assessed the 
therapeutic efficacy and safety of RFA for HCAs 
[Rhim et al. 2008], and reported their initial expe-
rience in 10 patients with 12 HCAs. Tumor sizes 
ranged from 1.5 to 4.5 cm. As no complications 
were reported after RFA, and no progression or 
recurrence was noted, RFA was considered a safe 
and effective treatment option. A minimal ablative 
margin of 5 mm is recommended during the radi-
cal treatment of lesions when using thermal abla-
tion of HCCs. It is presently unclear if a similar 
margin should be applied to HCAs, as these 
lesions are assumed to be benign. No data are yet 
available regarding the ideal ablative margin dur-
ing thermal ablation of HCAs. In our opinion, vol-
ume reduction is more important than an ablation 
margin, as the former correlates strongly with a 
risk of bleeding, and malignant transformation. 
Follow-up imaging after both RFA, and TAE, is 
routinely performed in our institution by MRI, 6 
months after treatment.
As HCAs requiring treatment are generally large 
(>5 cm), a promising alternative for RFA may be 
microwave ablation (MWA). Based on preliminary 
data, MWA was shown to produce larger ablation 
zones, in less time, in patients treated for HCC 
and colorectal metastases. MWA delivers high fre-
quency microwaves (0.9–2.4 GHz) into tumor tis-
sue, which causes fast spinning of molecules and 
thus destroys tissue. No data are available con-
cerning efficacy and complications after MWA. 
MWA has specific advantages over RFA, such as 
larger ablation zones, higher treatment tempera-
tures, and less susceptibility to local cooling by 
adjacent large blood vessels (heatsink). Although 
larger zones of ablation can probably be achieved 
by using single-electrode needles and MWA to 
treat HCAs, to the best of our knowledge, no data 
currently exists to substantiate this idea.
Transcatheter arterial embolization
As HCAs are hypervascular arterial lesions, bleed-
ing may be treated by selective transcatheter arte-
rial embolization (TAE) in cases where patients 
present with hemodynamic instability. 
Embolization of HCAs is a safe but relatively 
challenging procedure due to multiple small feed-
ing vessels [van Aalten et al. 2010]. Nonetheless, 
in cases of spontaneous rupture and bleeding, 
TAE should be considered as a first line treat-
ment as it is highly successful and minimally inva-
sive in an acute setting. Although high success 
rates have been described for TAE, there is only a 
sparse literature comparing TAE with either sur-
gery, or conservative management. In one study 
Karkar and colleagues described 52 patients with 
100 HCAs, of which 37% were treated with TAE 
[Karkar et al. 2013]. In most of these cases TAE 
was performed in a (semi) elective setting, with 
rupture and hemorrhage as indications in 20%, 
and suspected malignancy in 56%. Success rates 
of up to 92% were claimed for TAE (32), and of 
the 37 HCAs embolized, only 3 required second-
ary interventions (8.1%). All other embolized 
lesions were treated successfully; some disap-
peared (5/34), most decreased in size (22/34), or 
remained stable (7/34). Recurrence rates were 
also low. It is worth noting that the HCAs embo-
lized were relatively small, with a median diame-
ter of 2.6 cm. However, we feel that resection is 
indicated if malignancy is suspected and no 
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contraindications for surgery exist. In a report by 
Erdogan and colleagues, six HCAs were primarily 
embolized [Erdogan et al. 2007], four because of 
bleeding, and two electively, 1 year after bleeding. 
No complications were reported, and all HCAs 
ceased bleeding. A total of two of the lesions were 
resected after embolization, two regressed visibly 
on follow-up imaging, and two HCAs were only 
seen after resorption of hematoma on follow-up 
imaging. These last two patients were managed 
with a wait-and-see policy. In a retrospective 
study by Dheodar and colleagues, 17 emboliza-
tions were successfully performed in eight patients 
[Deodhar et al. 2011], with five patients undergo-
ing more than one embolization. The mean size 
of the treated HCAs was 3.6 cm, and regression 
was noted in all embolized HCAs after emboliza-
tion. As noted by Karkar and colleagues, TAE 
may also be used in an elective setting where no 
acute intervention is needed [Karkar et al. 2013]. 
This approach is of clinical interest and deserves 
further consideration.
Proposed management strategy
One of the major discussions on the management 
strategy of hepatocellular adenomas involves the 
clinical application of these recent findings in the 
dynamic field of adenoma subtyping. How should 
we take into account these new insights into daily 
practice? In our view, more data are needed to 
implement this subclassification in the diagnosis 
and treatment of adenomas, balancing the risk of 
an invasive liver biopsy with the additional bene-
fits in terms of individualized therapy and prog-
nostic stratification. A major effort should be 
made by expert centers involved in the diagnosis 
and treatment of hepatocellular adenomas to 
work on this collaboratively, preferably in research 
setting, to gather more data on the potential ben-
efits for an individual patient.
Based on our review of the current literature, we 
propose a management strategy applicable to most 
cases in which there is a suspicion of HCA (Figure 
5). This decision tree may not be appropriate for 
Figure 5. The management decision tree used in our tertiary academic medical center. This decision tree may 
not be appropriate for all patients; for some, a customized approach should be considered.
*One option is to biopsy those lesions where a subtyping diagnosis by imaging is impossible to achieve, or those lesions with 
typical signs of IHCA. Currently, this option is considered impractical given the large number of biopsies involved.
**Follow up is advised initially, at 6-monthly intervals. Thereafter, if the lesion shows no further alteration, follow up can 
be stopped, or repeated yearly until menopause. If the lesion is a typical H-HCA, follow up can be less stringent, possibly 
involving sonography, or MRI without contrast.
***Referral to an expert center is advised for the evaluation of any indication requiring intervention. This decision should be 
taken with consideration of contraindications (obesity, diabetes, centrally located tumor, ASA classification). Treatment can 
be primarily surgical, and in selected cases, RFA or local embolization.
b-HCA, β-catenin activated HCA; GSD, glycogen storage disease; HCA, hepatocellular adenoma; H-HCA, HNF1A-mutated 
HCA; IHCA, inflammatory HCA; M, months; RFA, radiofrequency ablation.
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all patients; for some, a more customized approach 
may be required. In standard situations, mainly 
when a lesion is >5 cm, OCs should be stopped 
and MRI performed after 6 months. If the lesion 
has contracted to <5 cm, clear signs of an H-HCA 
should be ruled in or out (Figure 1). In scenarios 
where H-HCAs are subsequently identified, ther-
apy can be less aggressive as inherent malignant 
progression is very low. Follow up is then advised, 
initially every 6 months, and if the lesion shows no 
further alteration, follow up can be stopped or 
simply repeated yearly until menopause [Marrero 
et al. 2014]. Since typical H-HCAs are easily iden-
tified using out-of-phase MRI sequences, intrave-
nous contrast can be obviated at follow up. A 
second option is to apply sonography during fol-
low up which is cheaper and less inconvenient for 
patients. For small lesions (<5 cm) that are cate-
gorized as IHCA, therapy should ordinarily not be 
altered (in standard cases). However, some may 
opt for a biopsy in order to exclude β-catenin 
mutation. This could also be the case if a subclas-
sification cannot be made with MRI. For larger 
lesions (>5cm) with a β-catenin mutation or if the 
patient has an aggravating status such as male sex, 
steroid use, glycogen storage disease, or underly-
ing viral hepatitis, intervention may be the first 
alternative. Treatment can be primarily surgical, 
and, in selected cases, RFA or TAE may be used. 
Depending on the underlying risks (obesity, dia-
betes, centrally located tumor), the best option 
would be to evaluate these patients in an expert 
referral center.
Conclusion
MRI is the preferred tool in the management of 
HCA, its current principle use being size evalua-
tion (cutoff 5 cm), identification of signs of malig-
nancy, and exclusion of H-HCAs, recognized for 
their benign course and permitting a conservative 
approach. Until now, there is no reliable MRI 
characteristic to diagnose non-invasively b-HCA, 
being the most important lesion to diagnose as it 
may have the highest malignant potential.
Conservative management remains the strategy of 
choice for uncomplicated small HCAs, and sur-
gery may be indicated if imaging shows heteroge-
neous signal and growing smaller lesions suspected 
of being highly-differentiated HCC. Further pro-
spective cohort studies are warranted to support 
the choices made between these treatment strate-
gies and to determine the role of biopsy in the sub-
classification of HCAs. In cases where a HCA 
requires treatment, and surgical resection of 
smaller lesions (<3 cm) carries an unacceptable 
risk, RFA or TAE may be considered.
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